# Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

> **NCT02384083** · PHASE1,PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 47 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Filanesib, pomalidomide and dexamethasone

## Key facts

- **NCT ID:** NCT02384083
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-02
- **Final completion:** 2020-03-23
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-07-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02384083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02384083, "Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02384083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*